Pages

▼
Showing posts with label bio. Show all posts
Showing posts with label bio. Show all posts
Wednesday, July 22, 2020

How should policymakers incentivize and regulate convalescent serum therapy for COVID-19?

›
By Jacob S. Sherkow , Lisa Larrimore Ouellette , Nicholson Price , and Rachel Sachs Over 120 years ago, a milk wagon horse named Jim was th...
Friday, July 10, 2020

How will the FDA’s new COVID-19 vaccine guidance affect development efforts?

›
By Rachel Sachs , Jacob S. Sherkow , Lisa Larrimore Ouellette , and Nicholson Price Policymakers are expectantly awaiting the development of...
Tuesday, April 23, 2019

How Does Patent Eligibility Affect Investment?

›
David Taylor (SMU) was interested in how patent eligibility decisions at the Supreme Court affected venture investment decisions, so he thou...
Monday, March 4, 2019

Recent Advances in Biologics Manufacturing Diminish the Importance of Trade Secrets: A Response to Price and Rai

›
Guest post by Rebecca Weires , a 2L in the J.D./M.S. Bioengineering program at Stanford In their 2016 paper, Manufacturing Barriers to Bio...
Tuesday, December 22, 2015

Burk: Is Dolly patentable subject matter in light of Alice?

›
Dan Burk's work should already be familiar to those who follow patentable subject matter debates (see, e.g., here , here , and here ). I...
Wednesday, December 2, 2015

Sampat & Williams on the Effect of Gene Patents on Follow-on Innovation

›
Bhaven Sampat (Columbia Public Health) and Heidi Williams (MIT Econ) are two economists whose work on innovation is always worth reading. I...
Thursday, July 23, 2015

The Latest on Biosimilars: The Federal Circuit Holds that the "Patent Dance" Is Optional

›
In a previous post, I  discussed a district court decision holding that the process for resolving patent disputes under the Biologics Pri...
Saturday, April 18, 2015

Price and Rai on Biologic Secrecy

›
Nicholson Price and Arti Rai just posted  Manufacturing Barriers to Biologics Competition and Innovation , which is forthcoming in the Iowa ...
Monday, April 13, 2015

Do Biosimilar Manufacturers Have To Dance? A District Court Answers “No”

›
In 2010, Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) as part of the Affordable Care Act. BPCIA is, in a broa...
Tuesday, January 20, 2015

Guest Post on Dan Burk's "Curious Incident of the Supreme Court in Myriad Genetics"

›
This is a guest post by Vikram Iyengar, a J.D. student at Stanford Law School. He thanks Prof. Mark Lemley for introducing him to Patent Law...
Monday, September 22, 2014

Patentable Subject Matter and Non-Patent Innovation Incentives

›
I just posted my symposium essay from U.C. Irvine's Meaning of Myriad Conference: Patentable Subject Matter and Non-Patent Innovation I...
Tuesday, September 16, 2014

IP Watch Recap of Meaning of Myriad Conference

›
Last Friday I presented my latest essay, Patentable Subject Matter and Non-Patent Innovation Incentives , at UC Irvine's Meaning of Myri...
Monday, March 26, 2012

Arti Rai – Patent Validity Across the Executive Branch: Ex Ante Foundations for Policy Development

›
What can the recent DNA patent controversies teach us about the role of executive agencies in shaping patent policy? In Professor Arti Rai’s...
Tuesday, April 19, 2011

Are Biotech Patents Enabled?

›
Stanford 3L Dmitry Karshtedt, who has guest posted on this blog , has a new post on Stanford's Law and Biosciences Blog about biologics...
Sunday, April 3, 2011

Heidi Williams: IP on Genes

›
How does intellectual property protection for human genes influence the development of products based on these genes? A few weeks ago, Heidi...
Monday, March 7, 2011

Robin Feldman on Owning You

›
The fourth paper in my review of Stanford's Bilski Symposium is Whose Body Is It Anyway? Human Cells and the Strange Effects of Proper...
Wednesday, March 2, 2011

Dreyfuss & Evans: Bilski and Gene Patents

›
Does Bilski bar patents on genetic diagnostics? All the Justices in Bilski agreed that patents may not "preempt" (or "pre-e...